Uncertainty in Revenue Recognition Due to Lengthy Development and Post-Launch Evaluation
First written in FY2017. 7 of 8 entries say "Restated". Latest entry: FY2023-Q3.
The whole theme swung hardest in 2018: 1 of 6 companies on the "Worse" side.
4 other companies' latest entry also says "Restated".
- FY2023-Q3RestatedAnnual report
「During the cumulative third-quarter period, there were no new business risks and no material changes in the business risks described in the annual securities report for the preceding fiscal year.」
The company has disclosed that there have been no material changes regarding the uncertainty over revenue recognition due to lengthy development and post-launch evaluation. - FY2020RestatedAnnual report
「Because it takes many years to progress from the start of basic pharmaceutical research to launch, it also takes a long time for the results of research and development to be recognized as business revenue.」
The company continues to disclose the uncertainty over revenue recognition due to lengthy development, development failure and insufficient market evaluation after launch. - FY2019RestatedAnnual report
「Because it takes many years to progress from the start of basic pharmaceutical research to launch, it also takes a long time for the results of research and development to be recognized as business revenue. In addition, the probability of success in pharmaceutical development has continued to decline in recent years, and many products do not reach launch, meaning that business revenue may ultimately not be recognized.」
The company continues to disclose the uncertainty over revenue recognition due to lengthy development, development failure and insufficient market evaluation after launch. - FY2019-Q1RestatedAnnual report
「During the cumulative first-quarter period, there were no new business or other risks and no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The company has disclosed that there have been no material changes regarding the uncertainty over revenue recognition due to lengthy development and post-launch evaluation. - FY2018RestatedAnnual report
「Because it takes many years to progress from the start of basic pharmaceutical research to launch, it also takes a long time for the results of research and development to be recognized as business revenue. In addition, the probability of success in pharmaceutical development has continued to decline in recent years, and many products do not reach launch, meaning that business revenue may ultimately not be recognized.」
The company continues to disclose the uncertainty over revenue recognition due to lengthy development, development failure and insufficient market evaluation after launch. - FY2018-Q3RestatedAnnual report
「During the nine months ended September, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」
The company has disclosed that there have been no material changes regarding the uncertainty over revenue recognition due to lengthy development and post-launch evaluation. - FY2018-Q2RestatedAnnual report
「During the six months ended June, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」
The company has disclosed that there have been no material changes regarding the uncertainty over revenue recognition due to lengthy development and post-launch evaluation. - FY2017First statedAnnual report
「Because it takes many years to progress from the start of basic pharmaceutical research to launch, it also takes a long time for the results of research and development to be recognized as business revenue. In addition, the probability of success in pharmaceutical development has continued to decline in recent years, and many products do not reach launch, meaning that business revenue may ultimately not be recognized.」
The risk of failing to achieve expected revenue due to the lengthy period from research and development to revenue recognition, development failure and insufficient market evaluation after launch has been disclosed independently for the first time.